Focus of research group (I)

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Miami CTSI--Culturalized Health Sciences for a Healthier South Florida! Clinical & Translational Science Institutes The U.S.A. launches an initiative to.
Biotechnology and Medicine Prof. S.K.Panda Department of Pathology All India Institute of Medical Sciences.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
Gene Therapy for Arthritis, Musculoskeletal, and Skin Diseases Group leaders and participants -Dr. Glen Nuckolls -Dr. Paul Robbins Program Director Professor,
Principles and Practices of Biosafety Environmental Health and Safety San Diego State University.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
The state stem cell agency September RFA 10-05: Disease Team Therapy Development Research Awards Educational Webinar September 9, 2011 Ellen G.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
Defining the right clinical problems for nanotechnology Table 2 John S. Oghalai, MD.
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York.
R EGENERATIVE M EDICINE I NTRODUCTION. Owes its inspiration to Greek mythology and the Story of Prometheus and Zeus: Greek myth says that Zeus had Prometheus.
NHLBI Gene Therapy Resource Program May 28, 2008 Sonia I. Skarlatos, PhD, FAHA Acting Director Division of Cardiovascular Diseases NHLBI Gene Therapy Coordinator.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
UWA, COVS and LEI COVS is effectively the academic arm of LEI through which competitive research grants are managed and to which academic appointments.
Gene Therapy AP Biology Unit 2 + What is Gene Therapy? A way to treat or cure diseases by inserting the “correct” DNA into the cell. Most promising for.
Biomedical Engineering
Jasna Marinović, M.D., Ph.D. Associate Professor Department of Physiology.
Achieving FDA approval for novel new nanomaterials Table 5 Eva M. Sevick, discussion leader Johnny Chen Amos Gaikwad Wah Chiu.
From bench to bedside on stem cell therapy for heart repair and vice versa: do we need a new consensus? John Martin British Heart Foundation Professor.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Critical Care Department St. Michael’s Hospital Research Program © 2003 Critical Care Dept, St. Michael’s Hospital.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
STEM CELL RESEARCH. What are stem cells? Cells that can generate more copies of themselves Have specialized function in body.
FUNDACION PUBLICA PROGRESO Y SALUD TECHNOLOGY TRANSFER OFFICE OF ANDALUSIAN PUBLIC HEALTH SYSTEM.
 (1) recombinant DNA technology or DNA cloning,  (2) reproductive cloning  (3) therapeutic cloning.
Vaccine Company Perspective Dr Gaurav Gupta, ZYDUS CADILA
Ann Intern Med. 2011;155(2): doi: / Figure Legend:
NIHR Invention for Innovation (i4i)
Gene therapy.
Clinical trial material & ATMPs
Biography Assistant Vice Chancellor for Commercial Translation in the Health Sciences Visiting Associate Professor, Department of Biomedical Informatics.
EULAR Gene and cell therapy Study Group
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
My life as a researcher. Fact or Fiction. How did I get here?
Appendix III: Scope of Service of CUHK Service Units
Monday, 23rd October, 2017, 5.00 p.m. c.t. Cluster of Excellence
EU funding opportunities
James M. Fadool Biological Science
Biomedical Engineer By: Amina Taslim.
Advancing Stem Cell Biology toward Stem Cell Therapeutics
Being an effective consumer of preclinical research
BMI: Regenerative Medicine
Non For Profit Model for Rare Disease Therapy Development
Genetic Engineering, Stem Cells, and Cloning
Gene Therapy: Past, Present, and Future
Volume 20, Issue 6, Pages (June 2017)
Focus of research group (I)
Focus of research group (I)
Focus of research group (I)
Focus of research group – AFib
Focus of research group (I)
Focus of research group (I)
Focus of research group (I)
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Regulation of Gene Therapy Products and Gametes Research in Hong Kong
Gene Therapy.
Nat. Rev. Cardiol. doi: /nrcardio
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Retreat Topics iPSC Opportunities in NIAMS Diseases
STRATEGIC ACTION IN HEALTH (AES)
Focus of research group (I)
Cardiac Stem Cell Therapy and the Promise of Heart Regeneration
Focus of research group - HCM
Presentation transcript:

Focus of research group (I) Name PI: Gerard Boink Department, UMC: Medical Biology, AMC Size of research group: 12 fte CARDIAC RHYTHM REGENERATION GROUP Current mission, vision and aims Aim: Improve heart rhythm management by novel regenerative therapies to prevent or cure cardiac arrhythmias. https://www.medischebiologie.nl/boink-group/

Focus of research group (II) Current expertise Cardiac Arrhythmias Translational Gene and Cell Therapy Vector Engineering: Adenovirus, AAV, Lentivirus Direct Reprogramming hiPSC-CMs: Models & Therapeutics Animal models Current funding ERC Starting Grant Health Holland (TKI) Medtronic Nederlandse Hartstichting Dekker ZonMw: Game Changer ZonMw: Meer Kennis Minder Proefdieren ZonMw: Veni

Future plans Short term (1-2 year) plan: In vitro function therapeutic viruses Proof-of-principle in vivo rhythm repair (animal models) Necessary infrastructure: Stem cell lab Virus production In vitro/ex vivo cardiac function measurement Relevant animal models cardiac rhytm disease Long term (>2 year) plan: Preclinical animal models Clinical trials biological pacemaker constructs GLP/GMP manufacture Trial support Collaborations in ACS: Connie Bezzina, Bas Boukens, Vincent Christoffels, Ruben Coronel, Frances de Man, Hanno Tan, Arie Verkerk

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.